TILT Biotherapeutics

Executive Summary

TILT Biotherapeutics is a clinical-stage biotechnology company developing next-generation oncolytic viral immunotherapies for solid tumors. Its lead candidate, TILT-123, is an intravenously administered oncolytic adenovirus designed to stimulate antitumor immunity and overcome immunosuppression. The company aims to address limitations of current immunotherapies by enabling systemic delivery and enhanced tumor infiltration. With a focus on hard-to-treat cancers, TILT-123 has shown potential in preclinical models and early clinical trials. The company's platform leverages a patented oncolytic virus technology that can be combined with other therapies, offering a versatile approach. As TILT progresses through Phase 1 trials, upcoming data readouts and strategic partnerships will be critical for validating its therapeutic potential and advancing toward pivotal studies.

Upcoming Catalysts (preview)

• Q2 2026Phase 1 interim efficacy and safety data for TILT-12360% success
• H1 2026Announcement of partnership or licensing deal for TILT-12340% success
• Q4 2026Initiation of Phase 2 trial design or first patient dosed50% success